Southeastern Medical Oncology Center, Goldsboro Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2001
NCT00025285
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Alternative names

Southeastern Medical Oncology Center - Goldsboro

Active Ingredients

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

irinotecan (Camptosar) (1 trial)

thalidomide (Thalomid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3